Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Guillain-Barre Syndrome Diagnostics Market Size & Share 2026-2035
Report ID: GMI13213
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Guillain-Barre Syndrome Diagnostics Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Guillain-Barré Syndrome Diagnostics Market Size
The guillain-barré syndrome diagnostics market was valued at USD 240 million in 2025, is projected to reach USD 250 million in 2026, advancing at a 6.4% CAGR (2026–2035), and is expected to reach USD 440 million by 2035.
Guillain-Barre Syndrome Diagnostics Market Key Takeaways
Market Leader: EUROIMMUN (Revvity) led with over 19% market share in 2025.
Leading Players: Top 5 players in this market include EUROIMMUN (Revvity), Natus Medical (Integra LifeSciences), Nihon Kohden, Thermo Fisher Scientific, Siemens Healthineers, which collectively held a market share of 58% in 2025.
The Guillain-Barré syndrome diagnostics market is evolving from a predominantly procedure-led diagnostic category toward a more integrated mix of electrophysiology, cerebrospinal fluid analysis, antibody testing, imaging, and interpretation software. Demand is shaped by the need to establish diagnostic confidence quickly in acute presentations while differentiating immune-mediated neuropathies that can require materially different clinical management.
GMI Analyst View
Based on input from industry experts, the market recorded a -0.4% year-on-year revenue change in 2025. JPY and EUR depreciation compressed USD-reported revenues in Japanese and European markets even as underlying diagnostic volumes continued to rise, creating a technically subdued base for subsequent local-currency expansion.
Guillain-Barré Syndrome Diagnostics Market Trends, Growth Drivers & GMI Forecast Outlook
Guillain-Barré syndrome requires timely diagnostic confirmation, but the ability to complete a full workup remains uneven across health systems. Clinical recognition, protocol formalization, and more accessible interpretation tools are therefore expected to determine where diagnostic demand converts into sustained commercial adoption. [1]World Health Organization. "Guillain-Barré Syndrome." who.int
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
The clinical value of multi-modal testing supports demand for complementary rather than interchangeable modalities. NCS and EMG characterize peripheral nerve dysfunction, while CSF examination and anti-ganglioside antibody panels can strengthen diagnostic confidence when presentation, timing, or subtype differentiation complicates interpretation. This protocol-based demand structure supports revenue across instruments, consumables, assays, and laboratory services within a single diagnostic episode.
Post-infectious surveillance also enlarges the institutional relevance of GBS diagnostics. Health systems addressing neurological sequelae linked to infectious exposure require pathways that can distinguish acute immune-mediated neuropathy from competing causes of weakness or paralysis. This dynamic favors laboratories and hospital departments that can coordinate electrophysiology, serology, and specialist review without delaying clinical decision-making.
AI-enabled interpretation is particularly consequential where qualified neurophysiology capacity is scarce. Automated waveform review can improve workflow consistency and enable centralized specialists to support a broader network of care sites. Commercial adoption, however, will depend on clinical validation, interoperability with established systems, reimbursement acceptance, and the ability of providers to integrate new software into acute neurological workflows.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
The neurologist workforce gap is a structural constraint on the Guillain-Barré syndrome diagnostics market because the availability of instruments alone does not ensure clinically interpretable testing. NCS and EMG require trained acquisition and expert interpretation, while referral pathways must connect suspected patients to facilities capable of completing diagnostic confirmation. Teleneurology and remote interpretation can mitigate this constraint, but their effectiveness depends on connectivity, equipment availability, technician training, and care-network coordination.
Diagnostic ambiguity also complicates standardization. GBS can overlap clinically with acute-onset chronic inflammatory demyelinating polyneuropathy and other immune-mediated neuropathies, making serial assessment important when symptoms evolve. Inconsistent diagnostic bundles across institutions can suppress predictable procurement patterns for assay panels and imaging workflows, particularly where payer rules do not support comprehensive initial testing.
GMI Analyst View
We view protocol completion, rather than epidemiological demand alone, as the central determinant of forecast performance. Markets that align specialist access, reimbursement, and coordinated testing will capture more diagnostic value per case, while settings reliant on isolated procedures will remain underpenetrated despite clinical need.
Guillain-Barré Syndrome Diagnostics Market Segment Analysis
By Test Type
Nerve Conduction Studies (NCS)
The Guillain-Barré syndrome diagnostics market generated USD 57 million from nerve conduction studies in 2025, and NCS is expected to account for 22.5% of market revenue by 2035. NCS remains foundational to differentiating demyelinating and axonal disease patterns, but its relative revenue weight is moderated as specialty immunoassays and software-supported interpretation gain a larger role in the diagnostic mix.
Immunological & Serological Assays
Immunological & serological assays accounted for 26.8% of market revenue in 2025 and are expected to reach USD 129 million by 2035. The segment benefits from increasing use of subtype-relevant anti-ganglioside antibody testing, particularly in complex or atypical presentations where serological specificity can complement electrophysiological findings and support more differentiated laboratory service offerings.
Lumbar Puncture / CSF Analysis
Lumbar puncture / CSF analysis generated USD 52 million in 2025 and is projected to advance at a 4.7% CAGR (2026–2035). CSF analysis retains a clinically important role in confirming albuminocytologic dissociation, although its revenue trajectory reflects its position as one element of a broader workup rather than a stand-alone diagnostic solution.
Electromyography (EMG)
Electromyography generated USD 38 million in 2025 and is projected to represent 14.7% of market revenue by 2035. EMG contributes valuable evidence in complex cases by helping characterize denervation and injury patterns, sustaining demand in specialist neurology settings even where NCS remains the primary electrophysiological procedure.
Imaging Tests
Imaging tests held a 7.7% market share in 2025 and are expected to generate USD 38 million by 2035. MRI and peripheral nerve ultrasound are most relevant where clinical findings are atypical or conventional results remain inconclusive, positioning imaging as a supplementary modality that can add diagnostic confidence rather than displace electrophysiology or serology.
Other Test Types
Other test types are projected to expand at a 13.6% CAGR (2026–2035) and account for 5.7% of market revenue by 2035. This category includes emerging point-of-care, biomarker, and software-enabled approaches whose commercial potential is tied to validation, regulatory progression, and their ability to extend diagnostic reach beyond highly specialized centers.
By End Use
Hospitals & Clinics
Hospitals & clinics accounted for 51.9% of market revenue in 2025 and are expected to generate USD 218 million by 2035. Acute presentation, inpatient monitoring needs, and access to multi-disciplinary diagnostic infrastructure make hospitals the principal setting for comprehensive GBS workups, particularly when rapid escalation to neurological or intensive care services is required.
Diagnostic Laboratories
Diagnostic laboratories generated USD 52 million in 2025 and are expected to reach USD 96 million by 2035. Their importance rises with the growing role of specialty antibody panels, which are often processed through centralized laboratories with immunoassay automation, quality systems, and established referral networks.
Specialty Neurology Clinics
Specialty neurology clinics held 14.9% of market revenue in 2025 and are forecast to grow at a 6.7% CAGR (2026–2035). These settings support follow-up assessment, atypical presentations, and referral-based electrodiagnostic evaluation, making them important channels for ambulatory testing and longitudinal clinical review.
Academic & Research Institutes
Academic & research institutes are projected to reach USD 34 million by 2035 and advance at a 7.2% CAGR (2026–2035). Their role in biomarker validation, protocol development, and rare-neurological-disease research supports earlier uptake of advanced assays and interpretation technologies before wider clinical diffusion.
Other End Use
Other end-use settings represented 3.8% of market revenue in 2025 and are expected to grow at an 8.8% CAGR (2026–2035). Public health laboratories, remote facilities, and mobile diagnostic initiatives provide an early indicator of whether GBS testing can reach populations that lack routine access to specialist neurology services.
GMI Analyst View
We expect the segment mix to favor diagnostic offerings that combine clinical specificity with operational scalability. Immunoassay automation and software-supported electrophysiology can create differentiated revenue pools, whereas modalities dependent on highly localized specialist capacity will face a more constrained adoption path.
Guillain-Barré Syndrome Diagnostics Market Regional Analysis
North America Guillain-Barré Syndrome Diagnostics Market Analysis
The Guillain-Barré syndrome diagnostics market in North America held a 36.2% share of global revenue in 2025 and is expected to reach USD 148 million by 2035. Mature reimbursement, strong hospital-based neurology infrastructure, and broad availability of electrophysiological and laboratory testing support regional leadership, while platform upgrades and specialty assay adoption sustain value growth.
U.S.
The U.S. generated USD 76 million in 2025 and is projected to account for 30.0% of global market revenue by 2035. Robust reimbursement coverage, large hospital systems, and a deep installed base of neurodiagnostic equipment support continued demand, although faster expansion in emerging markets is expected to reduce its relative global weight.
Canada
Canada is expected to reach USD 17 million by 2035 and grow at a 6.6% CAGR (2026–2035). Provincial health-system investment and academic neurology capacity support established access to core diagnostic procedures, while uneven rural coverage preserves an opportunity for networked specialist interpretation models.
Europe Guillain-Barré Syndrome Diagnostics Market Analysis
Europe generated USD 70 million in 2025 and is projected to grow at a 5.8% CAGR (2026–2035). Established public reimbursement systems, clinical guideline alignment, and a strong neuroimmunology laboratory base provide a durable foundation, although procurement discipline and variable capital budgets constrain the pace of premium-platform replacement.
Germany
Germany is projected to reach USD 28 million by 2035 and expand at a 5.1% CAGR (2026–2035). Comprehensive statutory coverage, university-hospital networks, and established neurology research programs support demand for advanced antibody panels and serial electrophysiological testing.
UK
The UK held 5.5% of global revenue in 2025 and is forecast to advance at a 4.9% CAGR (2026–2035). National Health Service procurement consolidation supports broad access to essential diagnostics but can limit pricing flexibility and favor suppliers able to compete effectively in centralized tenders.
France
France generated USD 11 million in 2025 and is expected to reach USD 19 million by 2035. Hospital investment in laboratory capacity and neurodiagnostic modernization supports adoption, while academic neurology networks maintain demand for specialized testing in complex and research-oriented cases.
Italy
Italy is expected to reach USD 14 million by 2035 and grow at a 5.8% CAGR (2026–2035). Recovery in regional healthcare capital expenditure and academic engagement with neuroimmunology testing support gradual modernization of diagnostic capabilities across major care centers.
Spain
Spain accounted for 3.0% of global revenue in 2025 and is projected to grow at a 6.4% CAGR (2026–2035). A relatively lower installed base of premium diagnostic platforms creates upgrade potential as regional health authorities expand neurology infrastructure and replace aging equipment.
Netherlands
The Netherlands is projected to reach USD 9 million by 2035 and represented 2.1% of global revenue in 2025. Its influence in GBS clinical research supports adoption of advanced antibody and biomarker testing at academic medical centers, despite its smaller absolute market scale.
Asia Pacific Guillain-Barré Syndrome Diagnostics Market Analysis
Asia Pacific is projected to reach USD 119 million by 2035 and grow at a 7.8% CAGR (2026–2035). Infrastructure expansion, rising diagnostic awareness, and substantial unmet need across diverse care settings support regional momentum, while the prevalence of axonal variants in parts of East Asia reinforces demand for subtype-relevant serological testing.
China
China generated USD 16 million in 2025 and is forecast to grow at a 6.1% CAGR (2026–2035). Hospital expansion beyond major metropolitan centers and increasing clinician familiarity with electrophysiological and serological differentiation are broadening the institutional base for diagnostic procurement.
Japan
Japan held 5.5% of global revenue in 2025 and is projected to grow at a 5.4% CAGR (2026–2035). A well-established domestic electrophysiology base supports continued procedure volume, while demographic pressures and USD translation effects moderate reported revenue growth.
India
India is expected to account for 5.0% of global revenue by 2035 and grow at a 9.4% CAGR (2026–2035). Expansion of private hospital networks, growing investments in diagnostic infrastructure, and a large, underserved population create substantial opportunity, although specialist and equipment shortages outside major cities remain material constraints.
South Korea
South Korea is projected to reach USD 12 million by 2035 and expand at a 7.2% CAGR (2026–2035). Strong health technology adoption, reimbursement support for advanced diagnostics, and a capable domestic medical-device ecosystem position the country for continued uptake of software-enabled neurodiagnostic systems.
Australia
Australia generated USD 4 million in 2025 and is expected to reach USD 7 million by 2035. Comprehensive tertiary-care coverage supports a mature diagnostic base, while expanded regional specialist services provide a measured pathway for incremental demand outside major urban centers.
Latin America Guillain-Barré Syndrome Diagnostics Market Analysis
Latin America is expected to reach USD 31 million by 2035 and advance at a 7.5% CAGR (2026–2035). Public-health awareness following arboviral outbreaks, combined with private hospital investment in major urban markets, is improving demand for structured diagnostic pathways, although access and reimbursement remain uneven.
Brazil
Brazil generated USD 7.5 million in 2025 and is forecast to grow at a 7.9% CAGR (2026–2035). Its large hospital sector, private insurance expansion, and academic participation in neurological research support demand for advanced immunoassays and electrophysiological testing.
Mexico
Mexico is projected to reach USD 9 million by 2035 and grow at a 7.2% CAGR (2026–2035). Demand is concentrated in major metropolitan care networks, making the expansion of diagnostic access beyond these hubs central to the market's longer-term development.
Argentina
Argentina accounted for 0.6% of global revenue in 2025 and is expected to reach USD 3 million by 2035. Academic neurology institutions and established specialty testing capabilities provide a resilient demand base despite broader economic constraints on healthcare procurement.
Middle East & Africa Guillain-Barré Syndrome Diagnostics Market Analysis
The Middle East & Africa region held 3.8% of global revenue in 2025 and is expected to reach USD 15 million by 2035. The market is highly polarized: Gulf states are expanding specialized care capacity, while specialist shortages and limited equipment access continue to restrict diagnostic completion across much of sub-Saharan Africa.
Saudi Arabia
Saudi Arabia generated USD 2.5 million in 2025 and is projected to reach USD 5 million by 2035. State-backed healthcare infrastructure investment and the development of tertiary neurology services are improving access to advanced diagnostic equipment and laboratory workflows.
UAE
The UAE is expected to reach USD 4 million by 2035 and expand at a 7.2% CAGR (2026–2035). Concentrated private and international hospital networks, purchasing capacity for advanced equipment, and a favorable environment for new diagnostic technologies support demand growth.
South Africa
South Africa accounted for 0.6% of global revenue in 2025 and is projected to reach USD 3 million by 2035. Academic medical institutions provide an important regional base for diagnostic capability, although access to NCS/EMG and specialist interpretation remains limited beyond large urban centers.
GMI Analyst View
We expect regional divergence to sharpen as reimbursement quality and specialist capacity increasingly determine whether clinical demand becomes completed diagnostic revenue. Asia Pacific offers the strongest expansion runway, while mature markets retain value leadership through installed-base depth, laboratory sophistication, and faster adoption of advanced workflows.
Guillain-Barré Syndrome Diagnostics Market Share & Competitive Landscape
The Guillain-Barré syndrome diagnostics market is moderately concentrated, with the five leading companies collectively accounting for 58% of market revenue in 2025. This Guillain-Barré syndrome diagnostics market share structure reflects a division between electrophysiology hardware specialists and laboratory-diagnostics providers, leaving room for companies that can connect testing modalities, workflow software, and centralized interpretation.
EUROIMMUN (Revvity) held a 19% market share in 2025. Its neuroimmunology portfolio positions the company strongly in anti-ganglioside antibody testing, while laboratory automation supports reference-laboratory customers seeking to consolidate specialized assay workflows and improve operational consistency.
Natus Medical (Integra LifeSciences) held a 14% market share in 2025. The company's electrodiagnostic franchise benefits from an installed base of NCS and EMG systems, recurring service relationships, and the commercial advantage of integrating neuromuscular testing with reporting and workflow tools.
Nihon Kohden held a 10% market share in 2025. Its strength in electrophysiology, particularly across Japan and Asia Pacific, is reinforced by remote-care capabilities that can extend specialist neurophysiology support to facilities with limited on-site expertise.
Thermo Fisher Scientific participates through its clinical laboratory infrastructure and specialty-diagnostics channels, while Siemens Healthineers is relevant through imaging, laboratory, and informatics workflows in large hospital systems. Abbott Laboratories, Cadwell Industries, DiaSorin S.p.A., Compumedics Limited, and Neurosoft LLC contribute to competition across serology, electrophysiology, and regional equipment niches. Emerging companies, including Ceribell Inc., Persyst Development Corporation, NeuroOne Medical Technologies Corporation, Medtronic plc (Neurology Diagnostics Division), Electrical Geodesics Inc. (Philips), Neurolutions Inc., and Neuros Medical Inc., illustrate the potential for adjacent neural-monitoring, software, and electrode technologies to influence future diagnostic workflow design.
Recent Industry Developments
In May 2025, Revvity announced the launch of the IDS i20 automated specialty-testing platform. The system is designed to support automated chemiluminescence immunoassay workflows, strengthening the company's ability to address laboratory demand for scalable specialty testing and reduced manual processing. [5]Revvity, Inc. "Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing." businesswire.com
In April 2025, Natus Medical announced the integration of its InVisus Pro neuromuscular ultrasound system into the Natus Elite software environment. The integration is intended to allow clinicians to review ultrasound, NCS, and EMG findings within a connected reporting workflow, supporting multimodal evaluation in complex peripheral nerve cases. [6]Natus Medical Incorporated. "Natus announces integration of InVisus Pro NMUS into Natus Elite software." prnewswire.com
In April 2025, Nihon Kohden announced the second-generation Live View Panel Pro platform for remote neurophysiology workflows. The platform supports centralized monitoring and specialist collaboration, representing a directional enabler for broader access to expert interpretation across distributed care networks. [7]Nihon Kohden. "Nihon Kohden Advances Remote Neurology Care with Second-Generation Live View Panel Pro." morningstar.com
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →